<table><tr><td>“Main Board”</td><td>the stock exchange (excluding the option market)
operated by the Stock Exchange which is independent
from and operated in parallel with the Growth Enterprise
Market of the Stock Exchange. For the avoidance of
doubt, the Main Board excludes the Growth Enterprise
Market</td></tr><tr><td>“Memorandum” or
“Memorandum of Association”</td><td>the eihhdgt amende and restated memorandum of
association of the Company adopted by special resolution
on October 8, 2019 with effect from Listing, as amended
from time to time, a summary of which is set out in the
section headed “Appendix IV – Summary of the
Constitution of the Company and Cayman Companies
Law”</td></tr><tr><td>“MOFCOM”</td><td>the Ministry of Commerce of the PRC (中華人民共和國
商務部)</td></tr><tr><td>“NDRC”</td><td>the National Development and Reform Commission (國
家發展和改革委員會)</td></tr><tr><td>“NMPA”</td><td>National Medical Products Administration (國家藥品監
督管理局) and its predecessor, the China Food and Drug
Administration (國家食品藥品監督管理總局)</td></tr><tr><td>“Nomination Committee”</td><td> the nomination committee of the Board</td></tr><tr><td>“Ocean Prominent”</td><td>Ocean Prominent Limited (越揚有限公司), a limited
liability company incorporated in the BVI on March 18,
2014, and one of the Com’pans subsidiyaries</td></tr><tr><td>“Offer Price”</td><td>the final Hong Kong dollar price per Offer Share (before
brokerage of 1%, SFC transaction levy of 0.0027% and
Stock Exchange trading fee of 0.005%) at which Shares
are to be subscribed or purchased pursuant to the Global
Offering, which will be not more than HK$8.95 and is
expected to be not less than HK$8.18, to be determined as
described in “Structure of the Global Offering – (E)
Pricing of the Global Offering” in this prospectus</td></tr><tr><td>“Offer Share(s)”</td><td>the Hong Kong Offer Shares and the International
Offering Shares, where relevant, with any Shares being
issued pursuant to the exercise of the Over-allotment
Option</td></tr></table>

<table><tr><td>“Over-allotment Option”</td><td>the option to be granted by our Company to the Joint
Global Coordinators (on behalf of the International
Underwriters) under the International Underwriting
Agreement pursuant to which our Company may be
required by the Joint Global Coordinators to allot and
issue up to 37,548,000 additional Shares, representing
approximately 15% of the Offer Shares initially available
under the Global Offering, at the Offer Price to cover
over-allocations in the International Offering, details of
which are described in the section headed “Structure of
the Global Offering” in this prospectus</td></tr><tr><td>“Over-allotment Shares”</td><td>up to 37,548,000 Shares which our Company may be
required to issue at the Offer Price pursuant to the
Over-allotment Option</td></tr><tr><td>“PRC Legal Advisor”</td><td>Commerce & Finance Law Offices</td></tr><tr><td>“Pre-IPO Incentivisation Plans”</td><td> the 2015 Pre-IPO Incentivisation Plan, the 2016 Pre-IPO
Incentivisation Plan and the 2018 Pre-IPO Incentivisation
Plan, the principal terms of which are set out in the
section headed “Appendix V – Statutory and General
Information – Pre-IPO Incentivisation Plans”</td></tr><tr><td>“Pre-IPO Investments”</td><td>the subscription of 55,500,000 Series A Preferred Shares,
125,976,000 Series B Preferred Shares, 145,506,500
Series C Preferred Shares, and 205,262,271 Series D
Preferred Shares by the Pre-IPO Investors at an aggregate
consideration of approximately US$244 million pursuant
to the Series A and B Share Purchase Agreement, Series
B Agreements, Series C Share Purchase Agreement,
Series D1 Share Purchase Agreement and Series D2
Share Purchase Agreement, further information on which
is set forth in the section headed “History, Development
and Corporate Structure – Pre-IPO Investment” in this
prospectus</td></tr><tr><td>“Pre-IPO Investors”</td><td>the Series A Preferred Shareholder, the Series B Preferred
Shareholders, the Series C Preferred Shareholders and the
Series D Preferred Shareholders</td></tr></table>